Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04452305

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Spermatogonial stem cell transplantation through ultrasound guided rete testis injection and testicular tissue grafting will be performed for participants who have frozen testicular tissue prior to gonadotoxic therapy. The purpose of this study is to test the safety and feasibility of these transplant technologies and restore fertility for these participants.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Magee-Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location status: Recruiting

Location contact

Rachel Neelley

CONTACT

[email protected]

412-641-7475 ext. 1

About this study

Azoospermia (no sperm in ejaculated semen) impacts 1% of men in the general population and 15% of infertile men, which translates to 645,000 males between the ages of 20 and 50 (prime reproductive years) in the United States. Spermatogenesis arises from a population of spermatogonial stem cells in the testes that maintain continuous sperm production throughout a man's post-pubertal life. Diseases or medical treatments that compromise the stem cell pool and/or prevent the stem cells from differentiating can cause infertility. Adult men have the option to cryopreserve a semen sample prior to therapy but this is not an option for prepubertal patients who are not yet producing sperm. This study will test the safety and feasibility of two approaches to restore sperm production using previously cryopreserved testicular tissues, which contain spermatogonial stem cells.

The first approach is autologous transplantation of testicular cells, including spermatogonial stem cells, into the testis using ultrasound-guided rete testis injection. The second approach is autologous grafting of intact pieces of testicular tissue under the skin in the scrotum.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male participant at least in Tanner stage 3
  • Previously cryopreserved and stored testicular tissue/cells (frozen due to an infertility-risking diagnosis or treatment such as chemotherapy or radiation) available for autologous transplantation and grafting
  • Healthy enough to undergo anesthesia
  • Written clearance for the procedure from the patient's hematologist or oncologist to confirm the patient has finished treatment for primary condition and are clear to undergo autologous stem cell transplant

Exclusion criteria

  • Participants considered to be high risk for surgical complications
  • Participants with a history of leukemia, lymphoma or testicular cancer or a cancer that likely involved testicles at the time of testicular tissue collection
  • Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent.

Treatment and study plan

Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting

Procedure

Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.

Primary outcomes

  1. Number of participants with return of spermatogenesis

    Time frame: 3 months-1year

    Rate of participants where sperm was found in semen analysis or testicular tissue analysis

Secondary outcomes

  1. Number of participants with cancer recurrence

    Time frame: 5 years

    Rate of participants diagnosed with cancer recurrence

  2. Number of participants with surgical complications of SSC transplantation and testicular tissue grafting

    Time frame: 3 months

    Rate of infection, hospital readmission, re-operation occurs

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer L Anglin

CONTACT

[email protected]

412-641-7475 ext. 1

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Registry information

Important dates

Study start
2023
Primary completion
2029
Study completion
2030
First posted
Jun 30, 2020
Registry last updated
Apr 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.